KRAS and pachyonychia congenita: However, KRAS G12C mutations only rarely occur in PC, and no targeted therapies have been approved for the other mKRAS variants, although some strategies, such as engineered exosomes and mKRAS-specific T lymphocytes, have shown interesting results [98,99].